SG11202112229UA - Cdk inhibitors - Google Patents
Cdk inhibitorsInfo
- Publication number
- SG11202112229UA SG11202112229UA SG11202112229UA SG11202112229UA SG11202112229UA SG 11202112229U A SG11202112229U A SG 11202112229UA SG 11202112229U A SG11202112229U A SG 11202112229UA SG 11202112229U A SG11202112229U A SG 11202112229UA SG 11202112229U A SG11202112229U A SG 11202112229UA
- Authority
- SG
- Singapore
- Prior art keywords
- cdk inhibitors
- cdk
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019085494 | 2019-05-05 | ||
| PCT/CN2020/088585 WO2020224568A1 (en) | 2019-05-05 | 2020-05-05 | Cdk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112229UA true SG11202112229UA (en) | 2021-12-30 |
Family
ID=73051265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112229UA SG11202112229UA (en) | 2019-05-05 | 2020-05-05 | Cdk inhibitors |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20220296595A1 (en) |
| EP (2) | EP3966213A4 (en) |
| JP (2) | JP2022531687A (en) |
| KR (1) | KR20220004755A (en) |
| CN (2) | CN114364675A (en) |
| AU (2) | AU2020269469A1 (en) |
| BR (1) | BR112021022105A2 (en) |
| CA (1) | CA3138973A1 (en) |
| CL (1) | CL2021002903A1 (en) |
| CO (1) | CO2021016504A2 (en) |
| EA (1) | EA202193015A1 (en) |
| IL (1) | IL287767A (en) |
| MA (1) | MA55909A (en) |
| MX (1) | MX2021013531A (en) |
| SG (1) | SG11202112229UA (en) |
| TW (2) | TW202108572A (en) |
| WO (2) | WO2020224568A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3085366A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| SG11202108004VA (en) * | 2019-01-29 | 2021-08-30 | Beta Pharma Inc | 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases |
| MA55909A (en) * | 2019-05-05 | 2022-03-16 | Qilu Regor Therapeutics Inc | CDK INHIBITORS |
| AU2021382769B2 (en) * | 2020-11-20 | 2024-03-07 | Hefei Institutes Of Physical Science, Chinese Academy Of Sciences | Dihydroisoquinolinone and isoindolinone derivatives and uses thereof |
| WO2023143482A1 (en) * | 2022-01-29 | 2023-08-03 | 上海辉启生物医药科技有限公司 | 2-aminopyrimidine compound or salt, preparation method therefor and use thereof |
| US20230322792A1 (en) * | 2022-04-08 | 2023-10-12 | Biolexis Therapeutics, Inc. | Cdk9 inhibitors |
| CN117645604A (en) * | 2022-09-05 | 2024-03-05 | 浙江同源康医药股份有限公司 | Compounds useful as CDK4 kinase inhibitors and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| EP1438053B1 (en) * | 2001-10-17 | 2008-09-10 | Boehringer Ingelheim Pharma GmbH & Co.KG | Pyrimidine derivatives, pharmaceutical agent containing said compounds, use and method for making same |
| US8258129B2 (en) * | 2006-07-06 | 2012-09-04 | Boehringer Ingelheim International Gmbh | 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments |
| JO2885B1 (en) * | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| TWI675028B (en) * | 2014-07-24 | 2019-10-21 | 美商貝達醫藥公司 | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof |
| CN105732615B (en) * | 2014-12-31 | 2018-05-01 | 山东轩竹医药科技有限公司 | Cdk kinase inhibitors |
| BR112017019286B1 (en) * | 2015-03-11 | 2023-02-14 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | SUBSTITUTED 2H-PYRAZOLE DERIVATIVES OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF |
| TWI736578B (en) * | 2016-02-06 | 2021-08-21 | 大陸商上海複尚慧創醫藥研究有限公司 | Certain protein kinase inhibitors |
| CN107286134B (en) * | 2016-04-11 | 2019-04-12 | 上海勋和医药科技有限公司 | 2,4- disubstituted pyrimidines derivatives are as CDK inhibitor and its application |
| PL3442947T3 (en) * | 2016-04-15 | 2023-10-02 | Epizyme, Inc. | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors |
| CN112225724B (en) * | 2016-09-07 | 2022-04-29 | 江苏豪森药业集团有限公司 | Benzimidazole compound kinase inhibitor and preparation method and application thereof |
| ES2917377T3 (en) * | 2016-12-22 | 2022-07-08 | Betta Pharmaceuticals Co Ltd | Benzimidazole derivatives, preparation procedures and uses thereof |
| CN108264512B (en) * | 2016-12-30 | 2022-05-03 | 上海医药集团股份有限公司 | Nitrogen-containing fused heterocyclic compound, preparation method, intermediate, composition and application thereof |
| CN108794452B (en) * | 2017-05-05 | 2021-05-28 | 上海时莱生物技术有限公司 | Compound with kinase inhibition activity, preparation method and application thereof |
| CN109503573A (en) * | 2017-09-14 | 2019-03-22 | 昆明圣加南生物科技有限公司 | 2- substituted anilinic pyrimidine derivatives and application thereof |
| US10519136B2 (en) * | 2017-12-29 | 2019-12-31 | Accutar Biotechnology | Dual inhibitors of PARP1 and CDK |
| CA3088381A1 (en) * | 2018-01-29 | 2019-08-01 | Beta Pharma, Inc. | 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof |
| MA55909A (en) * | 2019-05-05 | 2022-03-16 | Qilu Regor Therapeutics Inc | CDK INHIBITORS |
-
2020
- 2020-05-05 MA MA055909A patent/MA55909A/en unknown
- 2020-05-05 BR BR112021022105A patent/BR112021022105A2/en unknown
- 2020-05-05 US US17/608,915 patent/US20220296595A1/en active Pending
- 2020-05-05 KR KR1020217039756A patent/KR20220004755A/en unknown
- 2020-05-05 CN CN202080049033.9A patent/CN114364675A/en active Pending
- 2020-05-05 SG SG11202112229UA patent/SG11202112229UA/en unknown
- 2020-05-05 JP JP2021565881A patent/JP2022531687A/en active Pending
- 2020-05-05 WO PCT/CN2020/088585 patent/WO2020224568A1/en active Application Filing
- 2020-05-05 EP EP20802696.3A patent/EP3966213A4/en active Pending
- 2020-05-05 TW TW109114894A patent/TW202108572A/en unknown
- 2020-05-05 EA EA202193015A patent/EA202193015A1/en unknown
- 2020-05-05 CA CA3138973A patent/CA3138973A1/en active Pending
- 2020-05-05 AU AU2020269469A patent/AU2020269469A1/en active Pending
- 2020-05-05 MX MX2021013531A patent/MX2021013531A/en unknown
-
2021
- 2021-05-04 AU AU2021268648A patent/AU2021268648A1/en active Pending
- 2021-05-04 CN CN202180046122.2A patent/CN115803327B/en active Active
- 2021-05-04 JP JP2022567388A patent/JP2023525005A/en active Pending
- 2021-05-04 WO PCT/US2021/030728 patent/WO2021226140A1/en unknown
- 2021-05-04 US US17/922,804 patent/US20230174512A1/en active Pending
- 2021-05-04 EP EP21727336.6A patent/EP4146647A1/en active Pending
- 2021-05-05 TW TW110116234A patent/TW202144351A/en unknown
- 2021-11-01 IL IL287767A patent/IL287767A/en unknown
- 2021-11-04 CL CL2021002903A patent/CL2021002903A1/en unknown
- 2021-12-03 CO CONC2021/0016504A patent/CO2021016504A2/en unknown
-
2023
- 2023-09-26 US US18/373,060 patent/US20240066031A1/en active Pending
- 2023-09-26 US US18/373,067 patent/US20240033264A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240033264A1 (en) | 2024-02-01 |
| US20230174512A1 (en) | 2023-06-08 |
| TW202108572A (en) | 2021-03-01 |
| IL287767A (en) | 2022-01-01 |
| AU2020269469A1 (en) | 2021-12-09 |
| WO2021226140A1 (en) | 2021-11-11 |
| MX2021013531A (en) | 2022-02-11 |
| MA55909A (en) | 2022-03-16 |
| BR112021022105A2 (en) | 2021-12-28 |
| CN115803327A (en) | 2023-03-14 |
| EP3966213A1 (en) | 2022-03-16 |
| EP3966213A4 (en) | 2023-04-19 |
| US20240066031A1 (en) | 2024-02-29 |
| WO2020224568A1 (en) | 2020-11-12 |
| TW202144351A (en) | 2021-12-01 |
| CA3138973A1 (en) | 2020-11-12 |
| JP2022531687A (en) | 2022-07-08 |
| CL2021002903A1 (en) | 2022-07-08 |
| EP4146647A1 (en) | 2023-03-15 |
| KR20220004755A (en) | 2022-01-11 |
| US20220296595A1 (en) | 2022-09-22 |
| CO2021016504A2 (en) | 2022-01-17 |
| CN115803327B (en) | 2024-02-13 |
| CN114364675A (en) | 2022-04-15 |
| JP2023525005A (en) | 2023-06-14 |
| AU2021268648A1 (en) | 2023-01-19 |
| EA202193015A1 (en) | 2022-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | Kif18a inhibitors | |
| IL290341A (en) | Mta-cooperative prmt5 inhibitors | |
| IL287767A (en) | Cdk inhibitors | |
| EP3833355A4 (en) | Prmt5 inhibitors | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| IL289914A (en) | Enzyme inhibitors | |
| EP3817736A4 (en) | Pikfyve inhibitors | |
| ZA202106284B (en) | Rad51 inhibitors | |
| IL289863A (en) | Enzyme inhibitors | |
| IL276013A (en) | Pi4kiiibeta inhibitors | |
| IL289783A (en) | Enzyme inhibitors | |
| IL289778A (en) | Enzyme inhibitors | |
| IL288306A (en) | Combination therapies using cdk inhibitors | |
| IL283309A (en) | Rip1 inhibitors | |
| ZA202109573B (en) | Prmt5 inhibitors | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| EP3976797A4 (en) | Anti-crispr inhibitors | |
| IL280408A (en) | Cdk inhibitors and uses thereof | |
| EP3768256A4 (en) | Pan-tropic entry inhibitors | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| TWI844602B (en) | Kif18a inhibitors | |
| GB201914388D0 (en) | Kinase inhibitors | |
| GB201812462D0 (en) | Inhibitors |